Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | ARROW: an update on the registrational study

Mimi Hu • 21 Sep 2020
ESMO 2020
Thyroid Cancer Pralsetinib
ARROW

Mimi Hu, MD University of Texas MD Anderson Cancer Center, Houston, Texas, discusses promising results from the registrational Phase I/II ARROW trial (NCT03037385). This study investigated the safety of pralsetinib (BLU-667) in patients with advanced RET-positive mutation medullary thyroid cancer (RET+ MTC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Mimi Hu

Update on the efficacy and safety of the LIBRETTO-531 trial
3:06
Update on the efficacy and safety of the LIBRETTO-531 trial
Mimi Hu • 21 Sep 2020
Thyroid cancer at ESMO 2020
1:26
Thyroid cancer at ESMO 2020
Mimi Hu • 21 Sep 2020

Related Videos

ASCO guidelines update: systemic therapy sequencing in advanced thyroid cancer
3:09
ASCO guidelines update: systemic therapy sequencing in advanced thyroid cancer
Nabil Saba • 1 Jun 2026
Innovations improving outcomes and quality of life in thyroid malignancies
4:00
Innovations improving outcomes and quality of life in thyroid malignancies
Xiangqian Zheng • 6 Nov 2025
Patient-derived organoids guide personalized therapy in thyroid cancer
1:31
Patient-derived organoids guide personalized therapy in thyroid cancer
Mauro Cives • 18 Oct 2025
The evolving treatment landscape for BRAFm anaplastic thyroid cancer
1:35
The evolving treatment landscape for BRAFm anaplastic thyroid cancer
Mark Zafereo • 31 May 2025

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals